Phase 3 Stroke Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged between 18 and 80 years old
• People who have been diagnosed with a spontaneous brain bleed (not caused by injury or another known condition) in the upper part of the brain, confirmed by a brain scan
• People who arrived at hospital within 24 hours of their symptoms starting (or within 24 hours of when they were last seen to be well)
• People whose brain bleed covers an area of at least 10 mL on the scan, or any size if surgery has already been performed
• People with a stroke severity score above 8 on a standard medical scale called the NIHSS (confirm with trial site)
• People with a level of consciousness score of 8 or higher on a scale called the Glasgow Coma Scale (confirm with trial site)
• People for whom written consent has been provided — either by the patient themselves or by an approved person acting on their behalf

Who may not be able to join:

• People whose brain bleed was caused by a known underlying condition, such as an abnormal blood vessel, a brain aneurysm, a tumour, or a head injury — or where the bleed is a result of a stroke caused by a blockage
• People whose bleeding is only inside the fluid-filled spaces of the brain (isolated intraventricular haemorrhage)
• People with chronic kidney disease
• People considered very likely to pass away within 7 days, or who are unlikely to be able to follow the study treatment and check-up schedule
• People with serious ongoing health conditions that could affect how outcomes are measured, such as cancer, chronic lung disease, heart failure, or significant existing disability
• People who are pregnant or breastfeeding
• People who have previously had chelation therapy, or who have a known allergy or sensitivity to deferoxamine (one of the study drugs)
• People with severely low iron levels in the blood (haemoglobin below 7 g/dL or needing regular blood transfusions)
• People currently taking iron supplements containing more than 325 mg of ferrous iron
• People with a blood creatinine level above 2 mg/dL, which indicates reduced kidney function (confirm with trial site)
• People with known heart failure who are also taking more than 500 mg of vitamin C
• People who are allergic to colchicine (another study drug)
• People with certain bone marrow or severe liver or kidney conditions (confirm with trial site)
• People taking certain medications that are known to interact with colchicine, such as some antifungal medicines like ketoconazole or fluconazole (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.